LNTH News and Press, Lantheus Holdings Inc. From 02/25/20

Worldwide revenue of $89.3 million and $347.3 million for the fourth quarter and full year 2019, representing an increase of 3.6% and 1.2% over the prior year period, respectively Net income of $10.5 million and $31.7 million for the fourth quarter and full year 2019, representing a...

The boards of Lantheus Holdings ( LNTH -0.5% ) and Progenics Pharmaceuticals ( PGNX +11.4% ) have agreed to amend their merger agreement, first announced in October 2019. More news on: Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Merger & ac...

Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stock Transaction, Represents Approximately 40% Ownership Stake in Combine...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mar...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Tuesday, February 25, 2020, to discuss its financial and operating results for the fourth quarter and full year of 2019. To access the live confere...

Back in October, Lantheus Holdings ( LNTH ) and Progenics Pharmaceuticals ( PGNX ) publicized their agreement for Lantheus to purchase Progenics in an all-stock transaction. Despite some synergies between the companies, it appears a large portion of Progenics’ shareholders are not in ...

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today ...

Company Appoints Istvan Molnar, M.D. as Chief Medical Officer Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnost...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mar...

Lantheus’ Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics Lantheus’ In-Place Infrastructure and Commercial Capabilities Will Ensure the Progress of AZEDRA, and the PyL and 1095 Programs Lantheus Holdings, Inc. ( ...